We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Play the video to learn more
If you look, for instance, at the most recent ADA/EASD consensus for the treatment of hyperglycaemia in patients in type 2 diabetes, what is being made very clear is that the patient has to be at the centre of care. And, actually, what the consensus suggests is that we take steps to try to identify the specific needs of each individual and, even more, to provide specific solutions for those needs. What has been suggested, for instance, is that the key to assessing somebody is their characteristics. And there are, of course, many ways to characterise a patient. You can think of the phenotype and you can also think of the genotype – and genotyping can be very helpful in some cases.
“The patient has to be at the centre of care”

 

The goals of diabetes care are to prevent short- and long-term complications and optimise quality of life. The current consensus report from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) supports the use of a ‘Plan – Do – Check – Act’ cycle for implementing effective patient-centred diabetes care.

Patients’ individual characteristics and preferences remain central to therapeutic decision-making, informing individualised treatment goals and strategies to achieve those goals.

The presence of specific comorbidities or clinical characteristics of the patient, such as age, body weight or HbA1c, as well as the characteristics of individual agents or drug classes – including side effects, complexity or effect on HbA1c, body weight or incidence of hypoglycaemia – should be explored during a patient-centred discussion between patient and clinician.

For more on goals of care in type 2 diabetes management, visit the 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the ADA and EASD.

Select image for larger view

Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018 Dec;61(12):2461-2498.
http://www.ncbi.nlm.nih.gov/pubmed/30288571